WHAT
WE
INVEST IN
ARETI Europe backs early-stage HealthTech, BioTech, MedTech & Life Sciences ventures that combine regulatory compliance, clinical relevance, and commercial viability.
Our focus spans MedTech (Class IIb & III), Software as a Medical Device (SaMD), In Vitro and Molecular Diagnostics, Digital Health platforms with reimbursement logic, and Computational and AI-driven health solutions.
We invest from Seed through Series A+, focusing on European-origin or globally sourced ventures deploying across European markets.
ARETI Europe backs early-stage HealthTech, BioTech, MedTech & Life Sciences ventures that combine regulatory compliance, clinical relevance, and commercial viability.
Operating from dual headquarters in Copenhagen and Thessaloniki, we are positioned to vertically support Health Technology wherever the opportunity is confident, and the execution conditions are sustainable.
We prefer to avoid early-stage science experiments or speculative technology bets. We truly invest with a risk-averse approach where regulatory feasibility is real, clinical evidence is buildable, market access logic exists, and exit scenarios are visible.
What we do:
Execution Support
Backing a company is not just a backbone direction; exploring dynamics is simply the beginning of our work. ARETI Europe brings an integrated execution infrastructure that operates across four dimensions simultaneously.
On the regulatory front, we provide a classification strategy, quality management system implementation, technical documentation, notified body engagement, and post-market surveillance planning, thereby converting regulatory uncertainty into investability.
On the clinical side, we design buyer-grade study endpoints, develop feasible trial protocols, coordinate multi-site clinical studies, and integrate real-world evidence, translating scientific promise into market credibility.
On the market access aspect, we model health economics, map market pathways country by country, develop pricing logic, and sequence adoption across healthcare systems, converting approved products into deployable policies.
On the commercial and organizational aspect, we implement governance discipline, milestone-based planning, buyer-grade reporting, and talent structuring, converting promising companies into acquisition-ready assets.
Process
& Submission
Our process is designed to be rigorous, transparent, and founder-respectful. Initial screening focuses on three non-negotiable criteria: regulatory feasibility, executable evidence pathway, and visible exit logic.
If those are met, we move into deeper diligence across the team, technology, clinical strategy, and commercial positioning.
Our process is designed to be rigorous, transparent, and founder-respectful. Initial screening focuses on three non-negotiable criteria: regulatory feasibility, executable evidence pathway, and visible exit logic.
Knowing this space allows us to evaluate fast and make decisions clearly, without prolonged ambiguity. Founders who pass initial screening can expect direct engagement with our investment and operational team within a defined timeframe.
If ARETI Europe is the right partner for your venture, you will know early. If it isn’t, you will know that too. All it takes is that first step: clicking the button that will lead you to the application form.
Yes, this one